As of November 2018, there are over 40 clinical trials taking place in Iceland and registered with the NIH U.S. National Library of Medicine. These trials are structured to collect data for US-filing purposes and include those recruiting, enrolling by invitation, and active, but no longer recruiting. The types of trials include medical device, procedural, later stage drug trials, and long-running trials, such as the Generation Program.
According to the data, the most significant proportion of the clinical trials (40%) are currently in Phase 3 or 4. More than 50% of the clinical trials (21) are marked as funded by industry, including Novartis, Amgen, Gilead Sciences, Terumo, and many more, while 10% are funded through NIH funding. The two primary locations and research sites include the University of Iceland (Reykjavik, Iceland) and Landspitali University Hospital (Reykjavik, Iceland).
Pharmaceutical and drug development companies incorporated in Iceland benefit from low corporate tax and encouraging financial incentives for the clinical trial R&D and commercial applications. To learn more, please visit Invest in Iceland.